New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
10:06 EDTACT, TEVA, JBT, PKG, IP, PNFP, CMA, CHK, CFR, PGR, NVO, ADTN, ABC, CCL, BKH, CNP, KMB, SJM, NTI, MUOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Actavis (ACT) downgraded to Market Perform from Outperform at Wells Fargo... Adtran (ADTN) downgraded to Neutral from Buy at Mizuho... AmerisourceBergen (ABC) downgraded to Neutral from Buy at UBS... Black Hill (BKH) downgraded to Sector Perform from Outperform at RBC Capital... Carnival (CCL) downgraded to Neutral from Outperform at Exane BNP Paribas... CenterPoint Energy (CNP) downgraded to Underperform from Neutral at Credit Suisse... J.M. Smucker (SJM) downgraded to Sell from Neutral at Goldman... Kimberly Clark (KMB) downgraded to Sell from Neutral at Goldman... Northern Tier (NTI) downgraded to Hold from Buy at Dahlman Rose... Novo Nordisk (NVO) downgraded to Underweight from Neutral at JPMorgan... Progressive (PGR) downgraded to Underweight from Equal Weight at Evercore... Teva (TEVA) downgraded to Market Perform from Outperform at Wells Fargo... JBT Corporation (JBT) downgraded to Neutral from Buy at Sidoti... Packaging Corp. (PKG) downgraded to Underperform from Outperform at CLSA... International Paper (IP) downgraded to Outperform from Buy at CLSA... Pinnacle Financial (PNFP) downgraded to Market Perform from Outperform at Raymond James... Comerica (CMA) downgraded to Underperform from Market Perform at Raymond James... Cullen/Frost (CFR) downgraded to Underperform from Market Perform at Raymond James... Chesapeake (CHK) downgraded to Trim from Hold at Tudor Pickering... Micron (MU) downgraded to Negative from Neutral at Susquehanna.
News For ACT;ADTN;ABC;CCL;BKH;CNP;KMB;SJM;NTI;NVO;PGR;TEVA;JBT;PKG;IP;PNFP;CMA;CHK;CFR;MU From The Last 14 Days
Check below for free stories on ACT;ADTN;ABC;CCL;BKH;CNP;KMB;SJM;NTI;NVO;PGR;TEVA;JBT;PKG;IP;PNFP;CMA;CHK;CFR;MU the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 14, 2014
06:08 EDTPGRProgressive upgraded to Buy from Neutral at Citigroup
Citigroup upgraded Progressive to Buy on citing an attractive valuation and its belief underwriting spreads will improve. Citi raised its price target for shares to $29 from $27.
August 13, 2014
10:51 EDTPGRProgressive July EPS beat expectations, says Wells Fargo
Subscribe for More Information
10:12 EDTMUMicron management to meet with Needham
Subscribe for More Information
10:01 EDTCMAComerica Chief Credit Officer John Killian to retire in May 2015
Subscribe for More Information
08:28 EDTPGRProgressive reports July EPS 20c
Reports July net premiums written up 4% from prior year to $1.81B and net premiums earned up 5% to $1.74B.
August 12, 2014
14:28 EDTMUPacific Crest remains on the sidelines of Micron
Subscribe for More Information
07:55 EDTACTActavis recent weakness a buying opportunity, says Argus
Subscribe for More Information
August 11, 2014
11:58 EDTNVOMannKind rallies after inking licensing agreement with Sanofi
Subscribe for More Information
07:50 EDTMUMicron pullback creates buying opportunity, says Jefferies
Jefferies attributes the recent pullback in shares of Micron to Samsung's DRAM bit growth commentary and Micron's guidance for higher capital expenditures in FY15. Jefferies expects favorable DRAM supply/demand balance to continue through 2015 and thinks Micron will continue to see near-term pricing power. The firm recommends buying the stock at current levels and keeps a Buy rating on Micron with a $38 price target.
August 8, 2014
09:16 EDTNVONovo Nordisk management to meet with JPMorgan
Subscribe for More Information
09:10 EDTMUMicron shares should be bought on weakness, says Sterne Agee
Subscribe for More Information
August 7, 2014
13:55 EDTTEVATeva won't be meaningfully hurt soon by new Copaxone filing, says BMO Capital
After Teva (TEVA) confirmed that it received the first paragraph IV notice for the 3x per week version of its Copaxone drug from Dr. Reddy's (RDY), BMO Capital said it had expected companies to seek to market a generic version of the latest Copaxone formulation, but was surprised that Dr. Reddy's took this action. The firm notes that Teva's decision to file a lawsuit against Dr. Reddy over the application will trigger a 30 month stay of approval of the generic version,. BMIO Capital says that investors should keep this issue on their radar, but the firm does not expect Teva to be meaningfully hurt in the near-term by this development. It keeps an Outperform rating on Teva.
12:06 EDTTEVATeva will continue to defend COPAXONE intellectual property rights
Teva (TEVA) confirmed that it has received the first paragraph IV notice for its three-times-a-week COPAXONE 40 mg/mL product from Dr. Reddy’s Laboratories (RDY). Teva will continue to vigorously defend its COPAXONE intellectual property rights against infringement wherever they are challenged. Teva intends to file a lawsuit for patent infringement against Dr. Reddy’s within the 45 day period provided under the Hatch-Waxman Act. The filing of the lawsuit will trigger a 30 month stay of FDA approval of Dr. Reddy’s ANDA. COPAXONE 40 mg/mL is protected by two Orange Book patents that expire in 2030.
10:20 EDTTEVAMylan says litigation ins ongoing in India regarding Teva
Mylan (MYL) said that it expects Teva's (TEVA) efforts to seek an injunction will "as ineffective as it was in U.S. courts." The company said it will not provide further comment on the matter. Mylan said it will also postpone its 2014 Investor Day due to the ongoing nature of the Abbott (ABT) transaction. It expects its fully realized savings and profit from new products will not be realized till 2015. Comments taken from Q2 earnings conference call.
10:00 EDTCCL, CHKOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:28 EDTACTDepomed may add another pain product to portfolio, says Janney Capital
Subscribe for More Information
07:48 EDTCHKChesapeake upgraded at Stifel
As noted earlier, Stifel upgraded Chesapeake to Buy from Hold. The firm believes that the company's Q2 results confirm that the company is becoming well-positioned from a capex efficiency perspective heading into 2015. The firm expects the company's 2015 production to come in at the high end of guidance, and it thinks the stock has reached a good entry point. Target $34.
07:45 EDTCCLCarnival upgraded at BofA/Merrill
Subscribe for More Information
06:22 EDTCHKChesapeake upgraded to Buy from Hold at Stifel
Subscribe for More Information
06:21 EDTCCLCarnival upgraded to Buy from Neutral at BofA/Merrill
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use